We're raising our price target on Eli Lilly as the obesity-drug boom rolls on

The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.

Summary from the CNBC news feed. Copyright belongs to CNBC.

Opens in a new tab, so Investz stays open.

ShareEmail X LinkedIn Facebook Reddit WhatsApp

More headlines

CNBCAlaska Gov. orders probe of Peltola Senate campaign's alleged recruitment of 2nd Sullivan MarketWatchOur church has a $1.5 million bequest earning 3.75% in a bank account. Is inflation eroding it?CNBCHow Todd Gordon is trading Meta as the stock market rotates out of growth and into value names MarketWatch‘Fancy cars hold no appeal’: We have a 99% chance of outliving our life savings. Why not spend, spend, spend?CNBCBig Oil earnings are set to surge. Why investors may want to be cautious CNBCThird-quarter U.S. GDP increases a better-than-expected 3.4% as September inflation accelerates

Headlines and summaries come from publishers’ public news feeds and are shown with attribution and a link to the original. Investz does not write or endorse them and they are not investment advice. Disclosures.